Cardiff Oncology (NASDAQ:CRDF) , a clinical-stage biotech company specializing in new cancer treatments, saw its share price rise as high as $7.18 on Monday. It closed the day at $6.74, up about 7% from its previous close.
Over the past year, the stock’s per-share price has ranged from $4.88 to as high as $25.50. On Friday, investors learned that the company’s CFO, James E. Levine, bought 30,000 shares of the stock at $6.47 a share.
The company also presented positive phase 1b/2 trial news last week regarding onvansertib, its lead....More>>>
For the second day in a row, biotech stock Berkeley Lights (NASDAQ:BLI) suffered a big investor sell-off, falling by almost 12% on Thursday. Even though an analyst tracking the stock issued a bullish new research note on the company, it continued to experience the fallout from a sharply worded tweet storm delivered by a short seller.
Scorpion Capital’s six-tweet thread was published early on Wednesday, and it accused Berkeley Lights of “fleecing” both its customers and investors of its recent IPO.
The short seller said that....More>>>